阿帕替尼治疗晚期结直肠癌的临床试验观察  被引量:14

Clinical observation of apatinib in the treatment of advanced colorectal cancer

在线阅读下载全文

作  者:许翠洋 燕飞虎[1] 唐洁冰[1] 陶冀[1] 

机构地区:[1]哈尔滨医科大学附属第三医院内八科,黑龙江哈尔滨150081

出  处:《哈尔滨医科大学学报》2017年第3期250-253,共4页Journal of Harbin Medical University

基  金:吴阶平医学基金资助项目(320.6750.15229)

摘  要:目的探讨阿帕替尼治疗晚期结直肠癌的有效率和安全性。方法选择38例晚期结直肠癌患者作为治疗组,给予治疗组阿帕替尼500 mg qd口服治疗,同时选取同期、病理类型、分期、年龄相似的40例晚期结直肠癌患者作为对照组,接受中药支持治疗,分析两组患者治疗效果和不良反应发生率。结果治疗组的疾病有效控制率(15.8%)明显高于对照组的疾病有效控制率(2.5%),治疗组的无疾病进展期(PFS)(2.25月)和总生存期(OS)(5.28月)明显较对照组无疾病进展期(1.47月)和总生存期(4.22月)有所延长(P<0.05)。二组患者接受药物治疗后的不良反应无明显差异。结论晚期结直肠癌患者接受阿帕替尼治疗后能够取得生存获益,耐受性良好。Objective To investigate vanced colorectal cancer. Methods TAO Ji Affiliated Hospital of Harbin Medical University, the efficacy and safety of apatinib in the treatment of ad- Thirty-eight patients with advanced colorectal cancer were selected as the treatment group and treated with apatinit 500 mg qd. At the same time, 40 ca- ses of advanced colorectal cancer patients with the same period, pathological type, staging and age were selected as the control group and treated with Chinese medicine support treatment. The incidence of treatment and the incidence of adverse reactions were analyzed in both groups. Results The effective control rate ( 15.8% ) was significantly higher in the treatment group than in the control group (2.5%). PFS of treatment group extended (2.25 months) and OS extended (5.8 months) were significantly longer than the control group PFS extended ( 1.47 months) and OS extended (4. 22 months) ( P 〈 0. 05 ). There was no significant difference in the adverse effects of the two groups after receiving the drug treatment. Conclusion Apatinib has a beneficial benefit to patients with advanced colorectal cancer and less side effects.

关 键 词:阿帕替尼 晚期结直肠癌 酪氨酸激酶抑制剂 

分 类 号:R979.1[医药卫生—药品]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象